Evicenter
MarkdownMedical informationP&T meetings
Darovasertib (IDE196)

First-line metastatic uveal melanoma, in combination with crizotinib

Also known as LXS196
Manufacturer
IDEAYA Biosciences
Launch
Not announced
Last updated
206 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care

Immune checkpoint inhibitors

14 evidence topics · 11 sources

First-line nivolumab plus ipilimumab: single-arm phase 2 trial of the Spanish Multidisciplinary Melanoma Group, 52 participants

“This was a single-arm, phase II trial led by the Spanish Multidisciplinary Melanoma Group (GEM) on nivo plus ipi for systemic treatment-naïve patients of age > 18 years, with histologically confirmed MUM, Eastern Cooperative Oncology Group-PS 0/1, and confirmed progressive metastatic disease (M1).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Nivo (1 mg/kg once every 3 weeks) and ipi (3 mg/kg once every 3 weeks) were administered during four inductions, followed by nivo (3 mg/kg once every 2 weeks) until progressive disease, toxicity, or withdrawal.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“A total of 52 patients with a median age of 59 years (range, 26-84 years) were enrolled.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The primary end point was 12-month OS, which was 51.9% (95% CI, 38.3 to 65.5).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“The median OS and PFS were 12.7 months and 3.0 months, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote

“Nivo plus ipi in the first-line setting for MUM showed a modest improvement in OS over historical benchmarks of chemotherapy, with a manageable toxicity profile.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote